These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12004286)

  • 21. How do abacavir and efavirenz differ in pharmacokinetics and toxicity?
    Edmunds-Ogbuokiri J
    Fac Notes (New Orleans La); 1999; 11(3):1-4. PubMed ID: 11810867
    [No Abstract]   [Full Text] [Related]  

  • 22. New drugs: amprenavir and abacavir.
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
    Bollen P; Reiss P; Schapiro J; Burger D
    Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
    Jullien V; Tréluyer JM; Chappuy H; Dimet J; Rey E; Dupin N; Salmon D; Pons G; Urien S
    Br J Clin Pharmacol; 2005 Feb; 59(2):183-8. PubMed ID: 15676040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
    Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
    Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
    Khanlou H; Farthing C
    AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function.
    Izzedine H; Launay-Vacher V; Aymard G; Legrand M; Deray G
    Nephron; 2001 Sep; 89(1):62-7. PubMed ID: 11528234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
    Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
    Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.
    Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S
    Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.
    Jullien V; Urien S; Chappuy H; Dimet J; Rey E; Pons G; Blanche S; Tréluyer JM
    J Clin Pharmacol; 2005 Mar; 45(3):257-64. PubMed ID: 15703361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443.
    Allison AC; Almquist SJ; Muller CD; Eugui EM
    Transplant Proc; 1991 Apr; 23(2 Suppl 2):10-4. PubMed ID: 2063415
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.
    Kewn S; Hoggard PG; Sales SD; Jones K; Maher B; Khoo SH; Back DJ
    Antimicrob Agents Chemother; 2002 Jan; 46(1):135-43. PubMed ID: 11751124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-HIV agents. Abacavir only once-daily.
    TreatmentUpdate; 2003 Oct; 15(6):4. PubMed ID: 17216862
    [No Abstract]   [Full Text] [Related]  

  • 35. Abacavir pharmacokinetics in hepatic dysfunction.
    Wyles DL; Gerber JG
    Clin Infect Dis; 2005 Mar; 40(6):909-10. PubMed ID: 15736035
    [No Abstract]   [Full Text] [Related]  

  • 36. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
    Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B;
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug.
    Berenguer J; Padilla B; Estrada V; Martín C; Domingo P; Kindelán JM; Ruiz-Giardin JM
    AIDS; 2002 Jun; 16(9):1299-301. PubMed ID: 12045501
    [No Abstract]   [Full Text] [Related]  

  • 38. Mechanistic studies to understand the inhibition of wild type and mutant HIV-1 reverse transcriptase by Carbovir-triphosphate.
    Ray AS; Anderson KS
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1247-50. PubMed ID: 11562995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
    Falloon J; Piscitelli S; Vogel S; Sadler B; Mitsuya H; Kavlick MF; Yoshimura K; Rogers M; LaFon S; Manion DJ; Lane HC; Masur H
    Clin Infect Dis; 2000 Feb; 30(2):313-8. PubMed ID: 10671334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.